Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab Achieves Milestone in Arzerra Collaboration19 Apr 2010
Declaratory Relief Complaint for Patent Infringement under Patent based on Manufacture, Marketing and Sale of Arzerra25 Mar 2010
Genmab A/S summons Annual General Meeting24 Mar 2010
Genmab A/S Annual Report23 Mar 2010
Genmab to attend Kempen & Co Life Sciences11 Mar 2010
Genmab Announces Results from Zalutumumab Phase III Study of Refractory Head and Neck Cancer Patients8 Mar 2010
Financial Statements Release 20092 Mar 2010
Genmab Announces Year End 2009 Financial Results
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
2 Mar 2010
Arzerra 2009 Net Sales Figures4 Feb 2010
Genmab Outlicenses Zanolimumab to TenX Biopharma4 Feb 2010
Major Shareholder Announcement3 Feb 2010
Arzerra(TM) (Ofatumumab) Receives Positive Opinion for Conditional Approval in Europe for Refractory Chronic Lymphocytic Leukaemia22 Jan 2010
  • Previous
  • 1
  • More pages
  • 102
  • 103
  • 104
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863